ANRS, Emerging Infectious Diseases

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Diagnostics and Surveillance of Acute Meningo-encephalitis Among Children in Cambodia with a Focus on Japanese Encephalitis Virus

Not yet recruiting

Conditions: Japanese Encephalitis

First Posted Date: 2024-11-05

Last Posted Date: 2024-11-05

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 4000

Registration Number: NCT06674837

Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of High-grade Lesions and/or Anal Cancer 10 Years After Inclusion in the ANRS IPERGAY Trial

Not Applicable

Not yet recruiting

Conditions: Anal Cancer
HPV Infection

Interventions: Procedure: High-resolution anoscopy

First Posted Date: 2024-07-26

Last Posted Date: 2024-07-29

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 100

Registration Number: NCT06522256

Locations: 🇫🇷
Hôpital de la Croix Rousse - SMIT, Lyon, France
🇫🇷
Hôpital Saint-Louis - SMIT, Paris, France
🇫🇷
Hôpital Tenon - SMIT, Paris, France

Assisted Notification of Partners of Men Having Sex With Men Discovering Their Seropositivity

Not Applicable

Not yet recruiting

Conditions: HIV Infections

Interventions: Other: Partner notification by a trained counsellor

First Posted Date: 2024-05-17

Last Posted Date: 2024-05-23

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 400

Registration Number: NCT06419491

Study Evaluating the Safety, in Terms of HBV Virological Control at 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected With the HIV-1 and HBV Viruses

Phase 2

Not yet recruiting

Conditions: HBV Coinfection
HIV Infections

Interventions: Drug: TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI
Drug: Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR)

First Posted Date: 2024-04-01

Last Posted Date: 2024-08-20

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 140

Registration Number: NCT06338826

Negative Serology by Immunoenzymatic Test (EIA) in HIV-infected Children Treated Early With Antiretroviral in the ANRS-Pediacam Study: Pathophysiological Mechanisms

Not Applicable

Recruiting

Conditions: HIV Infections

Interventions: Biological: Blood sampling

First Posted Date: 2024-03-12

Last Posted Date: 2024-06-10

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 451

Registration Number: NCT06302933

Locations: 🇨🇲
Hôpital de Jour - Hôpital Laquintinie de Douala, Douala, Cameroon
🇨🇲
Service de Pédiatrie - Centre Hospitalier d'Essos, Yaoundé, Cameroon
🇨🇲
Unité Pédiatrique de Jour - Centre Mère et Enfant de la Fondation Chantal Biya, Yaounde, Cameroon

Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.

Phase 3

Not yet recruiting

Conditions: Prevention

Interventions: Drug: Tenofovir disoproxil/Emtricitabine 300mg/200mg fixed-dose combination tablets, for oral use
Drug: Cabotegravir Tablets, for oral use.
Procedure: Rectal Biopsies
Drug: Cabotegravir Extended-Release Injectable Suspension, for intramuscular use.

First Posted Date: 2024-02-23

Last Posted Date: 2024-02-23

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 322

Registration Number: NCT06273943

Locations: 🇫🇷
Hôpital Lariboisière, Paris, Ile De France, France
🇫🇷
Hôpital Saint Louis, Paris, Ile De France, France
🇫🇷
Hôpital Hôtel Dieu, Paris, Ile De France, France

and more 5 locations

Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.

Phase 1

Recruiting

Conditions: COVID-19

Interventions: Drug: CD40.RBDv vaccin (SARS-Cov2 Vaccin)

First Posted Date: 2024-02-13

Last Posted Date: 2024-06-12

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 240

Registration Number: NCT06255626

Locations: 🇫🇷
Hôpital Cochin, Paris, France
🇫🇷
Hopital Henri Mondor, Créteil, France

DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection

Phase 3

Not yet recruiting

Conditions: HIV-1-infection

Interventions: Drug: Doravirine + tenofovir DF + lamivudine
Drug: Dolutegravir + tenofovir DF + lamivudine or emtricitabine

First Posted Date: 2024-01-12

Last Posted Date: 2024-10-30

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 610

Registration Number: NCT06203132

Locations: 🇰🇭
National Center for HIV/AIDS, Dermatology and STD (NCHADS), Phnom Penh, Cambodia
🇧🇷
Laboratory on Clinical research on AIDS-INI FIOCRUZ, Rio De Janeiro, Brazil
🇨🇲
Yaoundé Central Hospital, Yaoundé, Cameroon

and more 3 locations

Feasibility and Effectiveness of a Pilot Program of Physical Activity to Improve HIV Related Functional Limitations and Disability in Adults Aged 40 and Older From Côte d'Ivoire

Not Applicable

Recruiting

Conditions: HIV Infections

Interventions: Procedure: Quantitative research
Behavioral: Qualitative survey

First Posted Date: 2023-11-18

Last Posted Date: 2023-11-28

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 450

Registration Number: NCT06139497

Locations: 🇨🇮
Formation semi urbaine (FSU) d'Abobo Avocatier, Abidjan, Côte D'Ivoire
🇨🇮
Centre Médical Spécialisé El Rapha, Abidjan, Côte D'Ivoire

Post-COVID-19 Condition: Observational Study in Vietnam

Not yet recruiting

Conditions: Post COVID-19 Condition

First Posted Date: 2023-09-01

Last Posted Date: 2023-09-01

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 835

Registration Number: NCT06022211

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy